|
Delaware
|
04-2825458
|
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
|
incorporation)
|
Identification No.)
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The Amendment extends the term of the Company's lease of its corporate headquarters in Burlington, Massachusetts, by six months (i.e., through September 30, 2009), at the same Annual Fixed Rent Rate as currently in effect. A copy of the Amendment is set forth as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
On April 10, 2008, the Company named Robert V. Linden to replace Mr. Kelly in the capacity of Vice President, North American Sales. Mr. Linden has been a member of the Company's sales force since 2002, most recently serving as the Company's Director of Sales for the Eastern United States and Canada.
The information set forth in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
(d) Exhibits.
Exhibit No. Description
10.1 Third Amendment of Lease
| |
|
LeMaitre Vascular, Inc.
|
||||||
|
Date: April 10, 2008
|
By:
|
/s/ Christopher H. Martin
|
||||||
|
Christopher H. Martin
|
||||||||
|
Assistant Secretary
|
||||||||
|
Exhibit No.
|
Description
|
|
|
EX-10.1
|
Third Amendment of Lease
|
|
|
EX-99.1
|
Press release issued by LeMaitre Vascular, Inc. on April 10, 2008, furnished herewith.
|
THIRD AMENDMENT OF LEASE
THIS AMENDMENT made and entered into as of the 26th day of February, 2008 by and between Rodger P. Nordblom and Peter C. Nordblom, as Trustees of Northwest Associates ("Landlord") and LeMaitre Vascular, Inc. ("Tenant").
WITNESSETH
WHEREAS, Landlord and Tenant entered into a lease dated March 31, 2003, as amended by the First Amendment of Lease dated May 21, 2004 and by the Second Amendment of Lease dated May 21, 2007 (collectively the "Lease") for the Premises containing 27,098 rentable square feet in the building located at 63 Second Avenue, Burlington, Massachusetts; and
WHEREAS, Landlord and Tenant would like to extend the term of the Lease for an additional six (6) Months expiring on September 30, 2009;
NOW THEREFORE, in consideration of the mutual agreements contained herein, the parties agree that the Lease shall be amended as follows, effective as of the date of this Amendment:
1. The Expiration Date as contained in Section 1.1 of the Lease, shall be changed to September 30, 2009.
2. The Annual Fixed Rent Rate and the Monthly Fixed Rent Rate specified in Section 1.1 of the Lease shall remain at $342,672 and $28,556.00 respectively through September 30, 2009.
3. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Lease.
As amended hereby, the Lease is ratified and confirmed in all respects, and shall continue in full force and effect.
The remainder of this page has been intentionally left blank
IN WITNESS WHEREOF, the parties have executed this Third Amendment of Lease under seal as of the date first written above.
LANDLORD:
/s/ Peter C. Nordblom
As Trustee and not individually
/s/ Rodger P. Nordblom
As Trustee and not individually
TENANT:
LEMAITRE VASCULAR, INC.
By: /s/ Trent G. Kamke
Print Name: Trent G. Kamke
Print Title: Senior VP-Operations
Hereunto duly authorized
LEMAITRE VASCULAR ANNOUNCES CHANGES TO ITS EXECUTIVE MANAGEMENT TEAM
Burlington, MA -- 04/10/2008 -- LeMaitre Vascular, Inc. (NASDAQ: LMAT - News) today announced the departure of Kevin D. Kelly, Senior Vice President, North American Sales, to pursue other business opportunities and the appointment of Robert V. Linden to Vice President, North American Sales.
Mr. Linden has approximately six years North American sales experience with LeMaitre Vascular. He joined LeMaitre Vascular in July 2002 as a Sales Representative and has served in positions of increasing responsibility within the North American organization. Since January 2008, he has served as Director of Sales for the Eastern United States and Canada, supervising three of the company's five North American sales regions. From 2005 through 2007, Mr. Linden served as Regional Sales Manager. Prior to LeMaitre Vascular, Mr. Linden served as a sales representative at several medical device companies, including Vasca, Inc., Atrium Medical Corporation, Active Medical, Inc., and DePuy Orthopedics, Inc. Mr. Linden holds a B.A. in Marketing from The Pennsylvania State University.
LeMaitre Vascular Chairman and Chief Executive Officer George W. LeMaitre stated, "We want to thank Kevin Kelly for his contributions and we wish him the best. We are thrilled to promote Rob Linden to the position of Vice President, North American Sales. I have watched Rob succeed at our company in positions of increasing responsibility over the past six years. We believe he will build on this experience to provide effective leadership for our North American sales organization."
About LeMaitre Vascular
LeMaitre Vascular develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease. The company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803.
Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. The forward-looking statements made in this release are made only as of the date hereof, and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.
CONTACT:
Aaron Grossman
Office: 781.221.2266
Investor Relations
LeMaitre Vascular, Inc.
SOURCE:
LeMaitre Vascular, Inc.